
Fore Biotherapeutics Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022
Fore Biotherapeutics (Fore Bio), a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients, announced the presentation of new data demonstrating that FORE8394, a next-generation BRAF inhibitor, provides evidence of durable anti-tumor activity and patient benefit in BRAF-mutated (V600+) cancers. Data from the ongoing Phase 1/2a study evaluating FORE8394 for the treatment of advanced solid and central nervous system (CNS) tumors with activating BRAF alterations were presented in a poster session at the European Society of Medical Oncology Congress (ESMO) taking place in Paris, France.
“I am extremely proud of the progress this team has made in advancing our next-generation, and potential best-in-class BRAF-inhibitor to address the limitations of the current standards of care and improve outcomes for patients with cancer,” said Matthew Ros, Chief Executive Officer of Fore Biotherapeutics. "These results are very encouraging and reinforce our conviction that FORE8394 has the potential to provide meaningful benefit to patients with BRAF-mutated cancers with high unmet need. We are embarking upon developing this novel treatment and are on track to initiate our global Phase 2 trial next quarter.”
As of the data cutoff date of July 31, 2022, 108 adults and children have received ≥1 dose of FORE8394 and are included in the safety population; 51 adults (≥18 years) met the criteria for the V600+ efficacy analysis; overall response rate (ORR) was 25.5% and median duration of response: 17.8 months. An additional analysis was conducted in the MAPK-inhibitor naïve subset, excluding patients with colorectal cancer (CRC) (N=21). Patients received 900-3600 mg/day of oral FORE8394 alone or with cobicistat (CYP3A4 inhibitor) to increase exposure, with the majority having been treated with total daily doses of 900-1800 mg.
Key Findings from the Ongoing Phase 1/2a Study
-
In MAPK inhibitor-naïve adult V600+ patients (N=21, excluding CRC), confirmed responses and durable benefit was seen across multiple tumor types
-
Clinical activity observed in this population includes ORR= 42.9%, clinical benefit rate ≥ 24 weeks= 71.4%, median duration of response was 17.8 months and median progression free survival (PFS) was 28.6 months
- In patients with primary CNS tumors, 4 of 4 patients with high grade glioma and 2 of 3 patients with low grade glioma experienced a partial response (PR) ; 1 had stable disease and remains on treatment after 15+ months
- Of 6 patients with papillary thyroid cancer, median PFS was not reached (median follow-up 5.6 years)
-
Clinical activity observed in this population includes ORR= 42.9%, clinical benefit rate ≥ 24 weeks= 71.4%, median duration of response was 17.8 months and median progression free survival (PFS) was 28.6 months
- Additional responses were observed in patients with V600+ ovarian cancer where 3 of 3 patients had PR; 2 having received prior MAPK-targeted treatments
-
FORE8394 demonstrated a favorable safety profile, with long-term tolerability, across the 108 patients
- Adverse events were transient and manageable
- Symptomatic adverse events (AEs) were low grade (Grade 1 or 2), mild and included fatigue, nausea, diarrhea & vomiting
- Hepatic laboratory changes were manageable with dose interruption or modification
- No secondary cutaneous skin malignancies or acanthomas occurred
- Only 1 participant discontinued treatment due to treatment related adverse event
"In this heterogeneous and heavily pre-treated patient population, the overall response rate and meaningful durations of response demonstrates the potential of FORE8394 to uniquely target tumors with BRAF alterations," said Stacie Shepherd, MD, PhD, Chief Medical Officer of Fore Biotherapeutics. "We're excited that the majority of gliomas demonstrated response and the prolonged benefit and tolerability experienced by some patients receiving FORE8394. Based on the strength of these findings, our Phase 2 study will further evaluate FORE8394 in patients with both solid and CNS tumors with BRAF fusions and recurrent primary CNS tumors with BRAF V600E mutations.”
“There are several limitations with first-generation BRAF inhibitors, including treatment resistance leading to disease progression and the paradoxical activation of the MAPK pathway, leading to secondary cutaneous skin cancers. In addition, these agents are inactive against class II BRAF alteration,” said Eric Sherman, MD, principal investigator and medical oncologist, Memorial Sloan Kettering Cancer Center. “These results suggest FORE8394 may provide meaningful benefit to patients, and we look forward to further exploring its potential in the upcoming Phase 2 study.”
About FORE8394
FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild-type forms of RAF. Preclinical studies and clinical trials have shown that its unique mechanism of action effectively inhibits not only the constitutively active BRAFV600 monomers targeted by first-generation RAF inhibitors but also disrupts constitutively active dimeric BRAF class II mutants, fusions, splice variants and others. Unlike first-generation RAF inhibitors, FORE8394 does not induce paradoxical activation of the RAF/MEK/ERK pathway. As a “paradox breaker,” FORE8394 could therefore treat acquired resistance to current RAF inhibitors and, more generally, yield improved safety and more durable efficacy than first-generation RAF inhibitors.
About Fore Biotherapeutics
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients. Its lead asset FORE8394 is a Class I/II BRAF inhibitor with demonstrated clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer-driving genes, the Fore R&D team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005184/en/
Contact information
Investors and Media:
Argot Partners
212.600.1902 | ForeBio@argotpartners.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Board Named a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:18:00 CET | Press release
Board, the global leader for Intelligent Planning Solutions, today announced that it has been named a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. The evaluation was based on specific criteria that analyzed Board’s overall Completeness of Vision and Ability to Execute. “We are thrilled to be named a Leader for the second consecutive year. We believe this recognition is indicative of the incredible value and positive impact our Intelligent Planning Solutions bring to global businesses,” said Jeff Casale, CEO of Board. “In today’s uncertain markets, organizations need a trusted enterprise partner to help innovate and enhance their financial planning and analysis processes to plan smarter and succeed faster. Our solution integrates planning processes in a single platform, offering strategy, finance, and operations with real-time analysis and data sharing, to deliver a truly intelligent approach.” A Gartner Magic Quadrant is a culmination of research in a spec
HCLTech Expands Footprint in Romania With New Global Delivery Center in Iași8.12.2023 15:56:00 CET | Press release
HCLTech, a leading global technology company, announced the launch of its new Global Delivery Center (GDC) in Iași, Romania. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231208755841/en/ Mayor of Iași, Mihai Chirica, cuts the inaugural ribbon of HCLTech’s new delivery center with the company’s CEO and MD, C Vijayakumar; its Romania country leader, Iulian Paduraru; and SVP, Shiv Walia. (Photo: Business Wire) The new state-of-the art center in Iași will provide next-generation digital, engineering, cloud and AI solutions. The center expands HCLTech’s presence in Romania and underscores its commitment to the country as part of its nearshore strategy to serve global clients. “This is a significant milestone for HCLTech in Romania as we continue our growth journey and serve our global clients with new capabilities in the latest technologies. We remain committed to our people and local communities and will continue investing in
Michelob Ultra Partners With Lionel Messi to Announce Being Named the Official Global Beer Sponsor of CONMEBOL Copa América USA 2024™8.12.2023 15:00:00 CET | Press release
AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), the world’s leading brewer, and CONMEBOL (Confederación Sudamericana de Fútbol), the governing body of South American football, will elevate their partnership with Michelob Ultra as the Official Global Beer Sponsor of Copa América USA 2024™. This renewed agreement deepens the company’s longstanding commitment to fans around the globe through the world’s most popular sporting events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231208607579/en/ Michelob Ultra partners with Lionel Messi to announce being named the Official Global Beer Sponsor of CONMEBOL Copa América USA 2024™ (Photo: Business Wire) Michelob Ultra is proud to also announce that CONMEBOL Copa América champion and global football icon, Lionel Messi, will be a new brand ambassador. He shared his excitement for the news: “I am so proud to join Michelob Ultra for its activations at CONMEBOL Copa América USA 2
COP28 Presidency Recognises ReNew as Clean Energy Transition Changemaker8.12.2023 14:50:00 CET | Press release
ReNew Energy Global Plc ("ReNew") (Nasdaq: RNW, RNWWW), India’s leading renewable energy company, has been named a Clean Energy Transition Changemaker by the COP28 Presidency for its work on the Round-the-Clock Power Project. Energy Transition Changemakers is a new COP28 UAE Presidency initiative which aims to foster private sector collaboration in delivering innovative and scalable decarbonization projects globally and demonstrate solutions to help enable and accelerate the energy transition. Sumant Sinha, Founder, Chairman and CEO, ReNew, said: “This recognition is testament to ReNew’s leadership and innovation in the renewable energy sector and our role as a leading decarbonisation partner." The ~1.3 GW Round-the-Clock Power Project is a first-of-its-kind project in India that is helping accelerate the just energy transition and ReNew is the only Indian company to be featured by the COP 28 Presidency as part of the Changemaker honours. ReNew’s wind and solar projects are already sup
Wilshire Completes Acquisition of Lyxor U.S.8.12.2023 14:00:00 CET | Press release
Wilshire, a leading global financial services firm, today announced the completion of its previously announced acquisition of Lyxor Asset Management Inc. (“Lyxor U.S.”), the U.S.-based investment advisor business of Lyxor Asset Management with $20.8 billion in assets under management1. This transaction brings together two firms that share an unwavering commitment to improving investment outcomes for clients. With the addition of Lyxor U.S., Wilshire is able to offer an enhanced suite of investment products and a leading alternatives platform to support a broader range of investment opportunities for clients of both legacy businesses. Financial terms of the transaction were not disclosed. About Wilshire Wilshire is a leading global financial services firm and trusted partner to a diverse range of more than 500 leading institutional investors and financial intermediaries. Our clients rely on us to improve investment outcomes for a better future. Wilshire advises on over $1.3 trillion in